Life science service provider Avantor and Cytovance Biologics, a biologics CDMO specialising in the manufacturing of high-quality plasmid DNA, have entered into an agreement to manufacture research and GMP grade plasmids for biopharma customers.
The collaboration extends Avantor’s offering of critical materials for vaccines and therapeutics focused on cell and gene therapy and mRNA drug manufacturing and expands Cytovance’s commercial reach.
The relationship will allow Avantor to provide global biopharma customers and CDMOs access to plasmid DNA and other mission-critical inputs used in research, clinical testing and manufacturing scale-up and commercialisation by leveraging Cytovance Biologics’ plasmid cGMP manufacturing capabilities.
"Demand for therapeutic biologics in the gene therapy space is increasing rapidly and will require increased manufacturing capacity and expertise,” said Dr Ger Brophy, Executive VP, Biopharma Production for Avantor. “Our collaboration with Cytovance Biologics demonstrates our commitment to cell and gene therapy biomanufacturers and will support our role in unlocking the potential these therapies hold for patients around the globe."
Naomi Seresinhe, Senior VP of Business Operations for Cytovance Biologics stated, “Production of plasmid DNA extends our microbial capabilities to support the growth of the cell and gene therapy space. We are delighted to be working closely with Avantor to support the biopharmaceutical industry on a global level.”
"Avantor looks forward to our collaboration with Cytovance Biologics to move science forward through expanding our capacity, educating customers on our unique capabilities, and engaging with new and potential customers in this growing space," added Dr Brophy.
